The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events

The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events

Immune checkpoint inhibitors (ICIs) have been approved for the treatment of many cancers, either in adjuvant or metastatic settings. Regarding safety, endocrine adverse events (AEs) are some of the most common AEs in ICI-treated patients, with thyroid dysfunction and hypophysitis being the most freq...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2023-03, Vol.15 (7), p.2016
Hauptverfasser: Mytareli, Chrysoula, Ziogas, Dimitrios C, Karampela, Athina, Papalexis, Petros, Siampanopoulou, Vasiliki, Lafioniatis, Alexandros, Benopoulou, Olga, Gogas, Helen, Angelousi, Anna
Format: Artikel
Sprache:eng
Schlagworte:
Adverse and side effects
Adverse events
Autoantibodies
Cancer
Cancer therapies
Case reports
Cohort analysis
Cushing's disease
Diabetes
Diabetes insipidus
Drugs
Endocrine disorders
Hypogonadism
Hypoparathyroidism
Immune checkpoint inhibitors
Immunotherapy
Lipodystrophy
Malignancy
Metastases
Oncology, Experimental
Osteoporosis
Pathogenesis
Pathophysiology
Patients
Pharmacovigilance
Side effects
Systematic Review
Thyroid
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Immune checkpoint inhibitors (ICIs) have been approved for the treatment of many cancers, either in adjuvant or metastatic settings. Regarding safety, endocrine adverse events (AEs) are some of the most common AEs in ICI-treated patients, with thyroid dysfunction and hypophysitis being the most frequent disorders. However, there are also some rare and very rare immune-related (ir) endocrine complications (incidence between ≥1/10,000 to
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15072016